

State of Oklahoma SoonerCare Idhifa[®] (Enasidenib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Pharmacy Billing (NDC:) Start Date (or date of next dose):	
Dose:	Regimen:	
	Billing Provider Informa	tion
Pharmacy NPI:	Pharmacy Name:	
Pharmacy Phone:	Pharmacy Fax:	
	Prescriber Informatio	on
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
i. Does member Yes Note ii. Will Idhifa® (iii. Has an IDHE) B. Is AML relapsed i. Will Idhifa® (ii. Has an IDHE) If answer is none of Additional Information:	(enasidenib) be used as a single-agent 12 mutation been detected? YesN lor refractory? YesNo(enasidenib) be used as a single-agent 2 mutation been detected? YesN fithe above, please indicate diagnost	nt? Yes No No nt? Yes No No sis:
3. Has the member experie		o enasidenib therapy? Yes No
the best of my knowledge.	treatment is medically necessary an	Date: nd all information is true and correct to ecessary. Failure to complete this form in full will

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.